Avanos and AIP Merger Receives Regulatory Approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 20 hours ago
0mins
Source: Newsfilter
- Merger Progress: Avanos Medical and American Industrial Partners announced the receipt of all necessary regulatory approvals, with the merger expected to close by July 27, 2026, marking a significant step in the company's strategic transformation.
- Shareholder Meeting Arrangement: Avanos will hold a special shareholder meeting on July 22, 2026, to vote on the merger proposal, ensuring shareholder support is crucial for the smooth execution of the transaction.
- Leadership Outlook: Avanos CEO David C. Pacitti stated that the regulatory approval is a result of strong collaboration between the two organizations, signaling the company's entry into a new phase of innovation and growth, enhancing its competitive edge in medical device solutions.
- AIP's Investment Potential: AIP, managing approximately $17.8 billion in assets, aims to drive Avanos's next phase of growth and commercial execution through their partnership, which is expected to deliver superior solutions in the medical device industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AVNS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AVNS
About AVNS
Avanos Medical, Inc. is a medical technology company focused on delivering medical device solutions. It offers healthcare needs, such as providing nutrition to patients from hospital to home and reducing the use of opioids while helping patients move from surgery to recovery. The Specialty Nutrition Systems portfolio of products includes enteral feeding, which consist of MIC-KEY enteral feeding tubes and Corpak patient feeding solutions, and Neonate solutions feeding products consist of NeoMed neonatal and pediatric feeding solutions. It also includes Nexus TKO, an anti-reflux needleless connector technology. The Pain Management and Recovery is a portfolio of non-opioid pain solutions including surgical pain and recovery products such as ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems, as well as Radiofrequency Ablation solutions, which provide invasive pain relief therapies, such as COOLIEF, Trident and ESSENTEC RFA products.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Merger Progress: Avanos and American Industrial Partners (AIP) announced the receipt of all necessary regulatory approvals, with the merger expected to close by July 27, 2026, marking a significant milestone in their collaboration and further driving Avanos's innovation and growth.
- Shareholder Meeting Scheduled: Avanos will hold a special shareholder meeting on July 22, 2026, to vote on the merger proposal, ensuring shareholder support is crucial for the smooth progression of the transaction, reflecting the company's commitment to stakeholder engagement.
- Leadership Outlook: Avanos CEO David C. Pacitti stated that the receipt of regulatory approvals is a result of strong collaboration, signaling the company's entry into a new phase of growth focused on delivering superior medical device solutions.
- AIP Investment Background: AIP manages approximately $17.8 billion in assets and focuses on investing in high-quality engineered product businesses, and post-merger, it will leverage its extensive industry experience and resources to support Avanos in achieving long-term value growth.
See More
- Merger Progress: Avanos Medical and American Industrial Partners announced the receipt of all necessary regulatory approvals, with the merger expected to close by July 27, 2026, marking a significant step in the company's strategic transformation.
- Shareholder Meeting Arrangement: Avanos will hold a special shareholder meeting on July 22, 2026, to vote on the merger proposal, ensuring shareholder support is crucial for the smooth execution of the transaction.
- Leadership Outlook: Avanos CEO David C. Pacitti stated that the regulatory approval is a result of strong collaboration between the two organizations, signaling the company's entry into a new phase of innovation and growth, enhancing its competitive edge in medical device solutions.
- AIP's Investment Potential: AIP, managing approximately $17.8 billion in assets, aims to drive Avanos's next phase of growth and commercial execution through their partnership, which is expected to deliver superior solutions in the medical device industry.
See More
- Strong Price Performance: Tactile Systems Technology's shares rose 8.1% in the last trading session, closing at $30.28 with significantly higher-than-average trading volume, reflecting market optimism about its future performance.
- Business Growth Momentum: The company continues to show growth in its lymphedema and airway clearance business lines, with expected quarterly earnings of $0.14 per share and revenues projected at $85.54 million, representing an 8.4% year-over-year increase.
- Stable Earnings Expectations: Although the consensus EPS estimate has remained unchanged over the past 30 days, the rising interest in Tactile Systems Technology indicates investor confidence in its future profitability.
- Industry Ranking Stability: Tactile Systems Technology currently holds a Zacks Rank of 3 (Hold), similar to its peer Avanos Medical, which also saw a slight increase in share price, indicating overall stability in the medical device sector.
See More
- Merger Investigation: Halper Sadeh LLC is investigating the merger between Corebridge Financial, Inc. and Equitable Holdings, Inc., where each share of Corebridge common stock will be exchanged for 1.0000 shares of the combined company, resulting in Corebridge shareholders owning approximately 51% of the new entity, which may affect shareholder rights and options.
- Shareholder Rights Protection: The law firm encourages shareholders of both Corebridge and Equitable to reach out to discuss their rights and options at no cost, indicating potential risks and legal issues that shareholders may face during the merger process.
- Avanos Medical Sale: Avanos Medical, Inc. is being sold to affiliates of American Industrial Partners for $25.00 per share in cash, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures on behalf of shareholders, highlighting the importance of protecting shareholder interests.
- Legal Service Commitment: Halper Sadeh LLC states that it will handle related matters on a contingent fee basis, meaning shareholders will not be responsible for legal fees, which aims to reduce the financial burden on shareholders and enhance their confidence in pursuing their rights.
See More
- Investigation Focus: Halper Sadeh LLC is investigating Apogee Therapeutics, Inc. (NASDAQ: APGE) for its sale to AbbVie at $135.11 per share, potentially infringing on shareholder rights.
- Shareholder Rights: Open Lending Corporation (NASDAQ: LPRO) is being sold to ANV Group Holdings Ltd. for $3.15 per share, with Halper Sadeh LLC urging shareholders to be aware of their rights and options.
- Legal Consultation: Huntsman Corporation (NYSE: HUN) is selling to Olin Corporation for 0.5476 shares of Olin per Huntsman share, and Halper Sadeh LLC offers no-cost legal consultations to help shareholders understand their legal rights.
- Compensation Requests: Avanos Medical, Inc. (NYSE: AVNS) is being sold to American Industrial Partners for $25.00 per share, and Halper Sadeh LLC may seek increased compensation and other relief measures to protect shareholder interests.
See More
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating Open Lending Corporation's transaction, where shareholders are expected to receive $3.15 per share in cash, reflecting the company's market value and potentially impacting shareholder confidence.
- Huntsman Corporation Transaction: Huntsman shareholders will receive 0.5476 shares of Olin Corporation for each share held, which may influence Huntsman's market performance and future strategic direction following the transaction.
- Cross Country Healthcare Shareholder Vote: Shareholders of Cross Country Healthcare, Inc. are expected to receive $13.25 per share in cash, with the shareholder vote scheduled for July 16, 2026, making this date critical for the company's future shareholder structure and market response.
- Avanos Medical Transaction: Avanos Medical shareholders will receive $25.00 per share in cash, with the shareholder vote set for July 22, 2026, indicating a potential restructuring of the company's capital and its competitive position in the market.
See More











